MARKET

EYPT

EYPT

EyePoint
NASDAQ
0.4041
+0.0422
+11.66%
After Hours: 0.4000 -0.0041 -1.01% 19:55 11/10 EST
OPEN
0.3650
PREV CLOSE
0.3619
HIGH
0.4085
LOW
0.3601
VOLUME
4.61M
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
0.3305
MARKET CAP
34.84M
P/E (TTM)
-0.1080
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EYPT last week (1102-1106)?
Weekly Report · 1d ago
Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NASDAQ · 11/02 14:00
Weekly Report: what happened at EYPT last week (1026-1030)?
Weekly Report · 11/02 09:11
EyePoint: DME Upside Remains, But Financing Could Consume Most Of It (Rating Downgrade)
Seeking Alpha · 10/29 09:05
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
NASDAQ · 10/28 13:00
Weekly Report: what happened at EYPT last week (1019-1023)?
Weekly Report · 10/26 09:11
EyePoint Pharmaceuticals (EYPT) was downgraded to a Hold Rating at JonesTrading
TipRanks · 10/23 20:16
EyePoint downgraded to Hold from Buy at Jones
TipRanks · 10/23 20:05
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.